Success of direct-acting, antiviral-based therapy for chronic hepatitis C is not affected by type 2 diabetes

Blake A. Niccum, Jonathan G. Stine, Javelle A. Wynter, Virginia Kelly, Stephen H. Caldwell, Neeral L. Shah

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic hepatitis C virus (HCV) is a risk factor for type 2 diabetes. In the era of interferon-based HCV therapy, type 2 diabetes was associated with decreased likelihood of sustained virologic response (SVR). Preliminary studies suggest that type 2 diabetes may not reduce the efficacy of regimens involving direct-acting antiviral (DAA) medications. We aimed to determine whether preexisting type 2 diabetes is associated with a reduced rate of SVR achieved 12 weeks after treatment of HCV with DAA-based regimens.

Original languageEnglish (US)
Pages (from-to)40-46
Number of pages7
JournalClinical Diabetes
Volume38
Issue number1
DOIs
StatePublished - Jan 2021

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this